See: Statistics from Altmetric.com Introduction Major neurocognitive disorders such as Alzheimers disease (AD), vascular dementia (VaD) and Parkinsons disease/Lewy body dementia (PD/LBD) are a major global health challenge.1 It is estimated that over 55 million people live with dementia globally, a number projected to reach more than 150 million by 2050.2 These diseases significantly impact patients and carers quality of life, while also placing a considerable burden on healthcare systems.3 Despite ongoing advances in understanding their physiopathology, effective treatmentsespecially disease-modifying onesremain limited.4 In this context, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being proposed as potential drugs for managing cognitive disorders owing to their putative ability to affect neurobiological and metabolic pathways implicated in neurodegeneration.5 GLP-1RAs are a class of medications currently including exenatide, lixisenatide, dulaglutide, liraglutide, semaglutide and tirzepatide (a dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist), initially developed for type 2 diabetes mellitus (T2DM).6 They mimic the action of endogenous GLP-1, which is secreted in response to nutrient intake and plays a key role in glucose homeostasishence the name incretin mimetics

Get in touch with our local Rocky River, OH team for bookings, questions, or assistance
PangZChongJZhouGde Lima MoraisDAChangLBarretteMet alMetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights
I love Natalie she is the best
More interestingly, several semimetallic nanomaterials, such as selenium (Se)- and tellurium (Te)-based nanoparticles, can also decrease intracellular GSH levels
Each plan is unique Every one of our clients receives a meticulously crafted treatment plan based on their individual skin and tattoo characteristics